DOCSLIB.ORG

Biocentury the BERNSTEIN REPORT on BIOBUSINESS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biocentury the BERNSTEIN REPORT on BIOBUSINESS WEEK OF MARCH 31, 2014 BioCentury THE BERNSTEIN REPORT ON BIOBUSINESS Volume 22 • Number 13 • Page A1 of 23 Regulation Viral crossroads By Steve Usdin BioCentury This Week Washington Editor Now that the family of seven-year-old Cover Story platform produces synthetic peptides with Josh Hardy has successfully obtained ac- the binding specificity and affinity of mAbs cess to an experimental drug, aided by an Viral crossroads — The Josh Hardy and many of the biological properties of explosion of social media support, law- case highlights the inadequacy of the small molecules./A13 makers, industry and patients still are left process for deciding when to grant access grappling with the fundamental inequities to experimental medicines outside of Finance and flaws of the U.S. system for granting clinical trials. It also may be a catalyst for compassionate access to investigational change. Steady Hand — LSP has survived 25 years as therapies. Josh Hardy Chronicles — While social a life sciences VC by making a few small changes The problems have existed for years, media users may be claiming the credit, in to an otherwise single-minded strategy fo- including the idiosyncrasies of who gets the end Chimerix and FDA had to clear a cused on investing in early stage European access to investigational drugs outside of way to provide brincidofovir to a handful biotechs./A14 clinical trials and the criteria companies of patients while opening a door for Ebb & Flow — Biotech slip-sliding away? use to make decisions that are often life- broader access via a bigger trial./A7 Endocyte tops up. Ysios’ new fund. and-death. Commentary: The Equitable Pathway NetScientific-Breakout Labs. Also: Epigenomics; The fact that individual companies have — It is possible to identify basic principles Exact Sciences; MannKind; Cellectis; Exelixis; been left to make these decisions on an ad that should underlie a transparent system Idera; Horizon Discovery; Zogenix, et al./A17 hoc basis inevitably fuels suspicions among for reviewing compassionate use requests, patients, family members and the public no matter who does the assessment./A9 Featured links this week/A21 about the motives for denying access. The difference in perspectives between Stock charts & tables/A22 companies focused on gaining regulatory Emerging Company Profile Company index/A16 approval and individuals trying to save Going Small — ImmuSmol’s antibodies desperately ill loved ones can make mutual suspicion curdle into antagonism. treat cancer by targeting small molecule TM BioCentury 100 Indicators metabolites involved in tumor immune See next page evasion./A12 Week ended 3/28/14 Building Better Binders — Indi PRICES VOLUME Molecular’s protein-catalyzed capture 4983.60 1113.7M shrs dn 8% up 11% FUELING THE FIRE Wall Street, ACA & Prices Tokyo Calling www.biocenturytv.com BIO Asia is less than two weeks away but there’s still time to register for this exclusive partnering forum. Details follow A23. See Program Notes on A5 Lace Up Your Boots Shipping Up to Boston Bio€quity Europe will explore what it takes for The rEVOLUTION Symposium in Boston will examine the organization and management companies to be promoted to the biotech of R&D to uncover new disruptive models. Premier League. Details follow A23. Registration link follows A23. BioCentury, THE BERNSTEIN REPORT ON BIOBUSINESS MARCH 31, 2014 PAGE A2 OF 23 Regulation, The guidance lists criteria FDA applies from previous page “I worry — are cases like to review expanded access applications, including a determination that the “poten- The rise of social media as an advocacy Josh’s going to set a tial benefit justifies the potential risks of tool now raises the prospect that medical new standard for how the treatment use with the drug and that and regulatory decisions will be tipped by those risks are not unreasonable in the a public outcry. patients pursue this?” context of the disease or condition to be As the Hardy case illustrates, patients treated.” or their relatives can generate hundreds of Richard Klein, FDA FDA must determine that providing thousands of supporters virtually over- expanded access “will not interfere with night, along with a wave of attention on FDA procedures development of the drug for the expanded television. In the heat of a media feeding access use, and that the patient cannot frenzy, it is impossible for a CEO to The medical, ethical, business and lo- gistical aspects of providing access to obtain the drug under another IND or communicate the complexities of drug protocol.” development and why the integrity of the investigational drugs can be complex and To reduce impediments to expanded regulatory approval pathway must be pro- contentious, but the regulatory pathway is straightforward. access, FDA does not require reporting of tected to get a drug to as many patients as outcomes data. possible. While companies, patients and the “Expanded access is designed for regu- And a CEO who says “no” is no match media sometimes accuse FDA of prevent- ing compassionate access to an investiga- lar doctors — treating physicians as op- for 100,000 angry Twitter messages and posed to research doctors — so reporting death threats from angry individuals who tional drug, data show the agency virtually requirements are minimized,” Klein told jump on the bandwagon. The threat of never denies requests. This does not mean patients always get BioCentury. FDA requires reports only demonization has led companies to be about basic safety information, such as wary of individuals and groups seeking to access to unapproved drugs. Requests for “serious and unexpected adverse events obtain compassionate use access to their access must be submitted by drug spon- sors or with their permission. Patients that may be related to the drug, for ex- products. ample liver failure,” he added. While the Hardy case reflects old prob- cannot apply directly to FDA, and the As a result, Klein noted, FDA only has lems, it also may be a game-changer. The agency will not process an application from a physician unless a sponsor is anecdotal information about the efficacy almost immediate and apparently extraor- of drugs provided under expanded ac- dinary effectiveness of Chimerix Inc.’s willing to provide access to its product. That does not mean FDA always cess. brincidofovir for Josh Hardy, coupled with In some cases, as with Chimerix’s the power of social media to push the plays a passive role. Agency officials brincidofovir, the agency works with com- company to find a way to provide access, sometimes reach out to companies to encourage them to provide access to panies to create a clinical trial that could have already led other families to pursue lead to a new approval or expanded indi- similar campaigns (see “The Josh Hardy investigational drugs, according to Ri- cation. Chronicles,” A7). chard Klein, director of FDA’s Patient Liaison Program. But while Josh Hardy’s response to The Hardy case also has prompted brincidofovir may have been dramatic, members of Congress, industry trade as- The agency has initiated expanded Klein noted the feedback FDA receives sociations, patient advocacy groups and access discussions with companies based on requests from patients, media coverage suggests that patients and physicians seek- individual companies to reassess the need ing expanded access are often over-confi- for new principles to guide compassionate and other triggers. dent about the potential for experimental access decision-making in the era of social Biotech executives report they’ve re- ceived calls from FDA relaying requests treatments to provide dramatic cures. media and patient empowerment. “Every now and then people will call Biotech industry leaders are suggest- from members of Congress for family mem- back and say, ‘We really appreciate the ing it may be time to shift some decisions bers or constituents to receive access to investigational drugs. help, but my mom has died’,” he said. “No about compassionate access off the shoul- one has ever called up and said, ‘I really ders of CEOs and onto new institutions to FDA has used the term “compassion- appreciate the help, and my mom’s great.’ help adjudicate requests for pre-approval ate access” in the past, but now it uses “expanded access to investigational drugs You would think they would be more access to medicines. likely to call if that happened.” All of this points to the need for public for treatment use.” According to guidance There are, however, numerous reports consensus on a transparent pathway for released in 2013, expanded access is in- tended “for patients with serious or imme- in the medical literature of positive re- making decisions about compassionate sponses to compassionate use treatments. access (see “Commentary,” A9 & “Decision diately life-threatening diseases or condi- For example, in 2009 German researchers Tree for Compassionate Use,” A11). tions who lack therapeutic alternatives.” reported in Blood that compassionate use of Nexavar sorafenib in five patients with acute myelogenous leukemia (AML) pro- duced “sustained regression before and This Week in SciBX after allogeneic stem cell transplantation.” And the first published report about Bitter Taste for Sinus Infections — A Penn study has shown that bitter taste agonists the efficacy of brincidofovir recounted the stimulate release of antimicrobial peptides in the sinuses, suggesting a new way to treat dramatic rescue of a pediatric transplant chronic rhinosinusitis. SciBX Table of Contents, A15. See next page BioCentury, THE
Load more

Recommended publications
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids Manufactured By: Date of Preparation: The Madras Pharmaceuticals (05/07/2019) Old Mahabalipuram Road Karapakkam, Chennai Marketed By: Panacea Biotec Ltd. New Delhi 1 PART I: HEALTH PROFESSIONAL Page No. INFORMATION SUMMARY PRODUCT INFORMATION 4 INDICATIONS AND CLINICAL USE 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5 ADVERSE REACTIONS 7 DRUG INTERACTIONS 8 DOSAGE AND ADMINISTRATION 8 OVERDOSAGE 9 ACTION AND CLINICAL PHARMACOLOGY 9 STORAGE AND STABILITY 9 DOSAGE FORMS, COMPOSITION AND PACKAGING 9 PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION 10 PART III: PATIENT INFORMATION 11 2 Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids 3 PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Dosage Form / Approved Indications Administration Strength Topical Sitcom LD Cream Euphorbia Prostrata is Euphorbia Prostrata indicated for: Extract 1.0% w/w 10 mg (containing 0.315–0.825 - Treatment of Bleeding mg total flavonoids Haemorrhoids calculated as apigenin- - In post- 7-glucoside and 1.26–4.4 haemorrhoidectomy. mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base.
    [Show full text]
  • Download This Issue
    UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Contents Foreword 83 UIP Chapter Meeting August 25th -27th 2019, Krakow – Poland 85 Charing Cross International Symposium - Vascular & Endovascular Challenges Update April 15th-18th 2019, London – UK 191 81 Vol 26. No. 3. 2019 Medical Reporters’ Academy The reports from the UIP chapter meeting and Charing cross international symposium were prepared by the following members of the Medical Reporters’ Academy: Roman BREDIKHIN (Russia) Kirill LOBASTOV (Russia) Daniela MASTROIACOVO (Italy) Mustafa SIRLAK (Turkey) Stanislava TZANEVA (Austria) and chaired by: Andrew NICOLAIDES (Cyprus) 82 UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Foreword The Medical Reporters’ Academy was co-founded in 1994 as a joint initiative by clinical and research venous disease specialists and Servier; with the main objective to develop an international group of young specialists with a core interest in venous disease drawn from various fields including dermatology, vascular surgery, angiology and/or phlebology. Each year the Medical Reporters’ Academy members are invited by Servier, to cover one of the most important international congresses for venous disease specialists. This year, the UIP Chapter Meeting, which was held in Krakow, Poland on August 25th- 27th, 2019 and the Charing Cross International Symposium: Vascular & Endovascular Challenges Update which was held in London, United Kingdom on April 15th - 18th, 2019 were selected because these congresses involved renowned international and national venous experts and young health care professionals providing a great opportunity to exchange ideas, explore strategies for vein care and discuss the latest trends & innovations in the field. Together with Andrew Nicolaides, the chairman of the group, the academy members explored the program of the congress, selected the events and presentations likely to present breakthroughs or new findings to attend, and wrote short reports.
    [Show full text]
  • DATA SUPPLEMENT Safety and Efficacy of Combination Nivolumab
    DATA SUPPLEMENT Safety and Efficacy of Combination Nivolumab Plus Ipilimumab in Patients with Advanced Melanoma: Results from a North American Expanded Access Program (CheckMate 218) F. Stephen Hodi, Paul B. Chapman, Mario Sznol, Christopher D. Lao, Rene Gonzalez, Michael Smylie, Gregory A. Daniels, John A. Thompson, Ragini Kudchadkar, William Sharfman, Michael Atkins, David R. Spigel, Anna Pavlick, Jose Monzon, Kevin B. Kim, Scott Ernst, Nikhil I. Khushalani, Wim van Dijck, Maurice Lobo, David Hogg 1 Supplementary Tables Table S1: Summary of adverse events reported between first dose and 30 days after last dose of the EAP therapy that required immune modulating medications in ≥1% of patients Nivolumab plus ipilimumab (N=754) Any grade, Grade 3–4, N (%)a N (%) Any adverse event 600 (80) 332 (44) Diarrhea 132 (18) 52 (7) Maculopapular rash 115 (15) 22 (3) Colitis 76 (10) 57 (8) Increased alanine aminotransferase 72 (10) 47 (6) Increased aspartate aminotransferase 58 (8) 32 (4) Rash 52 (7) 3 (<1) Pruritus 47 (6) 3 (<1) Pneumonitis 39 (5) 9 (1) Hypophysitis 38 (5) 5 (1) Autoimmune hepatitis 37 (5) 28 (4) Pruritic rash 29 (4) 0 Generalized pruritus 22 (3) 3 (<1) Nausea 20 (3) 5 (1) Adrenal insufficiency 18 (2) 3 (<1) Generalized rash 15 (2) 5 (1) Fatigue 14 (2) 3 (<1) Malignant neoplasm progression 12 (2) 11 (1) Arthralgia 12 (2) 2 (<1) Vomiting 12 (2) 2 (<1) Uveitis 11 (1) 1 (<1) Headache 11 (1) 1 (<1) increased transaminases 11 (1) 8 (1) Macular rash 11 (1) 2 (<1) Pyrexia 10 (1) 1 (<1) Increased lipase 10 (1) 9 (1) Acute kidney injury 9 (1) 6 (1) Hepatitis 9 (1) 6 (1) Cough 9 (1) 0 Acneiform dermatitis 9 (1) 0 Abdominal pain 8 (1) 2 (<1) aOne grade 5 adverse event (due to malignant neoplasm progression) was reported.
    [Show full text]
  • Malta Medicines List 25 7 07
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Zovirax™ Suspension 200mg/5ml Oral suspension Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4gAntiviral J05AB01 PoM Zovirax® 800mg Aciclovir Aciclovir Medovir 800 800mg Tablet Virucid 800 Virucid 400 400mg Tablet Zovirax® Cream 5% w/w Cream Refer to PIL Antiviral D06BB03 PoM Medovir Zovirax® Eye Ointment 3% w/w Eye ointment Refer to PIL Antiviral S01AD03 PoM Neotigason® 10mg Retinoid - Acitretin Capsule 35mg D05BB02 PoM Neotigason® 25mg Antipsoriatic Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Antidiarrhoeal and Activated Charcoal Biocarbon® 0.25g Tablet 5g A07BA01 OTC Antiflatulent Dentinox® Infant Colic 42mg/ml Oral suspension Drops Antifoaming agent - Activated Dimethicone Aero-OM® 100mg/ml Oral drops emulsion Refer to PILPreparation for colic A02X OTC or wind pain Aero-OM® 40mg Tablet Activated dimeticone, Antacid and Asilone Antacid Tablets 270mg 500mg Tablet Refer to PIL A02AB10 OTC Dried aluminium hydroxide Antiflatulent
    [Show full text]
  • Novel Therapies for Treating Diabetic Retinopathy
    International Journal of Molecular Sciences Review Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy Mark T. Bolinger and David A. Antonetti * Departments of Ophthalmology and Visual Sciences, Kellogg Eye Center, and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48105, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-734-232-8230 Academic Editor: Lu Cai Received: 20 June 2016; Accepted: 30 August 2016; Published: 7 September 2016 Abstract: Diabetic retinopathy is the leading cause of blindness in working age adults, and is projected to be a significant future health concern due to the rising incidence of diabetes. The recent advent of anti-vascular endothelial growth factor (VEGF) antibodies has revolutionized the treatment of diabetic retinopathy but a significant subset of patients fail to respond to treatment. Accumulating evidence indicates that inflammatory cytokines and chemokines other than VEGF may contribute to the disease process. The current review examines the presence of non-VEGF cytokines in the eyes of patients with diabetic retinopathy and highlights mechanistic pathways in relevant animal models. Finally, novel drug targets including components of the kinin–kallikrein system and emerging treatments such as anti-HPTP (human protein tyrosine phosphatase) β antibodies are discussed. Recognition of non-VEGF contributions to disease pathogenesis may lead to novel therapeutics to enhance existing treatments for patients who do not respond to anti-VEGF therapies. Keywords: diabetic retinopathy; diabetic macular edema; cytokine; VEGF; TNF-α; blood retinal barrier; corticosteroid; renin-angiotensin system; kinin-kallikrein system; angiopoietin; vitreomacular adhesion 1. Introduction Diabetic retinopathy (DR) is a serious threat to vision that is poised to become even more problematic with the increasing worldwide incidence of diabetes.
    [Show full text]
  • Anaesthetic Antacids: a Review of Its Pharmacological Properties and Therapeutic Efficacy
    International Journal of Research in Medical Sciences Parakh RK et al. Int J Res Med Sci. 2018 Feb;6(2):383-393 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180005 Review Article Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy Rajendra Kumar Parakh*, Neelakanth S. Patil Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India Received: 13 December 2017 Accepted: 27 December 2017 *Correspondence: Dr. Rajendra Kumar Parakh, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids.
    [Show full text]
  • Cardiovascular System Drug Poster
    Cardiovascular Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Ethanol Glyceryl Trinitrate Anestisine Quinidine Procaine Adrenaline Adenosine Phenylepherine Heparin Vasoxyl Sotradecol Xylocaine Pronestyl Betamethasone Catapres Cedilanide Dopamine Inversine Metaraminol Acetyldigitoxin Hydrocortisone ( Ethanol ) ( Nitroglycerin ) ( Benzocaine ) ( Quinidine ) ( Procaine ) ( Epinephrine ) ( Adenosine ) ( Phenylephrine ) ( Heparin ) ( Methoxamine ) ( Sodium Tetradecyl Sulfate ) ( Lidocaine ) ( Procainamide ) ( Betamethasone ) ( Clonidine ) ( Deslanoside ) ( Dopamine ) ( Mecamylamine ) ( Metaraminol ) ( Acetyldigitoxin ) ( Hydrocortisone ) VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE Approved 1700s Approved 1879 Approved 1890s Approved 1900s Approved 1903 Approved 1920s Approved 1929 Approved 1930s Approved 1935 Approved 1940s Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1951 Approved 1952 Approved 1952 Regitine Phenoxybenzamine Serpasol Rescinnamine Diuril Harmonyl Naturetin Hydrochlorothiazide Hydrocortamate Fastin Ismel
    [Show full text]
  • 18Th Meeting of the European Venous Forum 29 June - 1 July, 2017 Porto, Portugal
    18th Meeting of the European Venous Forum 29 June - 1 July, 2017 Porto, Portugal Alfaˆ��n����������ega Porto �ongre������ss� �������enter, Porto, Portugal SCIENTIFIC PROGRAMME AND BOOK OF ABSTRACTS EDIZIONI MINERVA MEDIca Under the auspices of: International Union of Angiology Union Internationale �e Phlébologie – International Union of Phlebology Senior Corporate Members The European Venou� Forum i� extremely grateful to the following companie� for their continue� generou� �upport Senior Corporate Members BSN me�ical Me�tronic SERVIER SIGVARIS Management AG Corporate Members Kreussler Pharma Pierre Fabre © 2017 – EDIZIONI MINERVA MEDICA S.p.A. – �or�o Bramante 83/85 – 10126 Torino Web �ite: www.minervame�ica.it / e-mail: minervame�ica@minervame�ica.it All right� re�erve�. No part of thi� publication may be repro�uce�, �tore� in retrieval �y�tem, or tran�mitte� in any form or by any mean�. CONTENTS Welcome me��age …………………………………………………………………………………………………………… IV �ommittee� ………………………………………………………………………………………………………………………… V Foun�er Member� …………………………………………………………………………………………………………… IX �ongre�� Information …………………………………………………………………………………………………… XIII Scientific Programme Information …………………………………………………………………………… XVI Scientific Programme ………………………………………………………………………………………………… XVII Thursday 29 June 2017 …………………………………………………………………………………………… XVII Fri�ay 30 June 2017 ………………………………………………………………………………………………… XIX Satur�ay 1 July 2017 ……………………………………………………………………………………………… XXII Electronic Presentations ………………………………………………………………………………………… XXV Industry Sponsored
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen Et Al
    US008821928B2 (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen et al. (45) Date of Patent: Sep. 2, 2014 (54) CONTROLLED RELEASE 5,869,097 A 2/1999 Wong et al. PHARMACEUTICAL COMPOSITIONS FOR 6,103,261 A 8, 2000 Chasin et al. 2003.01.18641 A1 6/2003 Maloney et al. PROLONGED EFFECT 2003/O133976 A1* 7/2003 Pather et al. .................. 424/466 2004/O151772 A1 8/2004 Andersen et al. (75) Inventors: Pernille Hoyrup Hemmingsen, 2005.0053655 A1 3/2005 Yang et al. Bagsvaerd (DK); Anders Vagno 2005/O158382 A1* 7/2005 Cruz et al. .................... 424/468 2006, O1939 12 A1 8, 2006 KetSela et al. Pedersen, Virum (DK); Daniel 2007/OOO3617 A1 1/2007 Fischer et al. Bar-Shalom, Kokkedal (DK) 2007,0004797 A1 1/2007 Weyers et al. (73) Assignee: Egalet Ltd., London (GB) 2007. O190142 A1 8, 2007 Breitenbach et al. (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1052 days. DE 202006O14131 1, 2007 EP O435,726 8, 1991 (21) Appl. No.: 12/602.953 (Continued) (22) PCT Filed: Jun. 4, 2008 OTHER PUBLICATIONS (86). PCT No.: PCT/EP2008/056910 Krogel etal (Pharmaceutical Research, vol. 15, 1998, pp. 474-481).* Notification of Transmittal of the International Search Report and the S371 (c)(1), Written Opinion of the International Searching Authority issued Jul. (2), (4) Date: Jun. 7, 2010 8, 2008 in International Application No. PCT/DK2008/000016. International Preliminary Reporton Patentability issued Jul.
    [Show full text]
  • Imaging Mitochondrial Dynamics in the Adult Heart
    Imaging Mitochondrial Dynamics in the Adult Heart Thesis submitted by Siavash Beikoghli Kalkhoran BSc (First class Hons.), MSc (Distinction) For the degree of Doctor of Philosophy University College London, UK. Institute of Cardiovascular Science The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX. October 2017 Declaration I, Siavash Beikoghli Kalkhoran, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. The assistance and contribution of individuals to the generation of results are acknowledged within the methods sections of each chapter. 2 Dedicated to Soheila & Taher 3 Abstract Background Mitochondrial dynamics, the phenomenon which incorporates inter-mitochondrial communication and changes in mitochondrial morphology is central to cellular homeostasis. Although the phenomenon of mitochondrial dynamics has been comprehensively studied under normal and pathological conditions in non-cardiac cells, and more recently in cardiac cell lines, its relevance to adult cardiomyocytes has not been so well-established and is investigated in this thesis. Methods and Results Using 2D and 3D electron microscopy, we initially evaluated the morphological features of the 3 different mitochondrial subpopulations (interfibrillar, peri-nuclear, subsarcolemmal) in adult rodent cardiomyocytes, and demonstrated that they are morphologically unique. These morphological characteristics were found to be altered under pathological conditions such as ischaemia or the genetic ablation of mitochondrial fusion proteins “mitofusins”. Using mice expressing the Dendra2 fluorescence probe, we then confirmed that mitochondrial fusion events (“the inter- mitochondrial communication”) occur in live adult cardiomyocytes, and the fusion rates differ according to the mitochondrial subpopulation.
    [Show full text]
  • Egyptian Drug Guide 2011
    Abimol.Afrin.Betaserc.Daflon.Concor. Epilat.Trio.Epilat.Adalat.Effox.Indral. Maaloxplus.Lipitor.Zolam,Rivo ,D.D.B Panadol.Extra..visineAntiv.VitBBetolv ex.Amaryl.Blokium.Ator.Cidrophage.Egyptian Drug Guide 3rd Edition Avandia.Cardura.Cozaar.DiaBetolvex.2011 Daflon.Hyzaar.Migranil.Reparil.PanadDepartment of Pharmacy Practice and Clinical Pharmacy ol.Mylogin.Voltarin.Telfast.Septriun.S olocortef.Viagra.Tenedene.Tequin.Cla ritine.Epilat.Adalat.Effox.Indral.Maalo xplus.Lipitor.Tavanic.Proximol.Soluco rtef.Visceralgine.Zocor.Tenedone.Clar inase.Dolphen.Novalgin.Colona.Duxil. Eucarbon.Excedrin.Flagyl.Feldene.Di nitra.Anafranil.Comtrex.Librax.Lipost at.Neurobion.Predforte.avandemet.A vendia.Avendemet.Abilaxine.Concor. pon.Tenedone.Clarinase.Dolphen.Col Department of Pharmacy Practice and Clinical Pharmacy Table of Contents DRUGS FOR NEUROLOGIC DISORDERS .................................................................................................................. 5 PAIN MANAGEMENT ........................................................................................................................................... 5 ANALGESIC, ANTI-INFLAMMATORY AND ANTI- PYRETIC DRUGS ............................................................................................. 5 ANALGESIC AND ANTIPYRETICS ...................................................................................................................................... 7 OPIOID ANALGESICS ...................................................................................................................................................
    [Show full text]